The CENTERSTONE trial has demonstrated that Xofluza, a single-dose oral medicine, reduces the transmission of influenza virus from an infected person to household members by 32%. This is the first global phase III trial to show the benefit of an antiviral in reducing the spread of a respiratory virus. Reducing the spread of infection within households could help limit transmission within institutions and communities, potentially easing the burden of both seasonal and pandemic influenza on healthcare systems. The trial met its primary endpoint, showing that Xofluza taken by people infected with influenza reduced the odds of untreated household members contracting the virus. Xofluza was well tolerated, with no new safety signals identified. Results from the CENTERSTONE trial have been submitted to health authorities, including the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Influenza poses a significant health and economic burden, particularly for those at high risk of influenza-related complications. Every year, seasonal influenza infects an estimated one billion people worldwide and causes millions of hospitalizations, with up to 650,000 deaths globally. The co-circulation and burden of multiple respiratory viruses, including COVID-19, make it more important than ever to have effective options to treat and prevent the spread of influenza. Xofluza is approved in more than 75 countries for the treatment of uncomplicated influenza types A and B.